Email Updates

You are here

Home

14 OCTOBER 2022 VOLUME 24 ISSUE 41

Media Coverage

  • Watch a Man Living with HIV Confront His Criminalization Accuser

    Among the many resources available to those who access the new (and entirely free) HIV Justice Academy, an online resource for those interested in addressing HIV criminalization, is a new edit of a video created ten years ago. At the time, Sean Strub was in the early process of founding what would become SERO Project, an organization fighting HIV criminalization and helping to create networks of people living with HIV.

    October 14, 2022
    General
    POZ Magazine

  • “If You Are Uncomfortable in the Room Then You Are in the Right Place” – Reflections on Anti-Racism and Decolonizing Global Health From the International AIDS Conference in Montreal

    For the first time in its history, the International AIDS Conference (#AIDS2022) – the largest gathering of HIV and AIDS experts and activists – hosted a satellite session, focusing on institutional racism and decolonizing global health.

    October 13, 2022
    General
    PLOS Blogs

  • The Pediatric Drug Pipeline Should Include Improvements to Current HIV Treatment, Long-Acting Formulations and Antibodies

    Priorities for the development of new HIV medications for children include a complete dolutegravir-based regimen than can be mixed with water, an improved protease inhibitor for second-line treatment and injectable cabotegravir for infant prophylaxis. Looking further forward, a World Health Organization group recommends the development of new technologies such as skin patches that would make adherence easier and investigation of broadly neutralising antibodies for infants.

    October 13, 2022
    Treatment
    aidsmap

  • George W. Bush To Be Honored in Washington on World AIDS Day

    Former President George W. Bush and his wife, Laura, are returning to Washington next month to be recognized for their work on combatting HIV/AIDS worldwide. The US Global Leadership Coalition announced Thursday that it will honor Bush and the former first lady on World AIDS Day, Dec. 1, during its annual Tribute Celebration. The Bushes will receive the Global Leadership Award for establishing the President's Emergency Plan for AIDS Relief, or PEPFAR, in 2003. Bush announced the program in his State of the Union address in January 2003. He signed legislation to establish it in May 2003.

    October 13, 2022
    General
    ABC News

  • HIV Surge Sparks Emergency Summit Amid Global Alarm

    Experts from around the world have gathered for an emergency HIV meeting amid warnings the world is now losing the battle against the virus. More than 1.5 million new infections were reported globally last year – three times more than global targets. Health experts from the 28 countries with the highest rates of new infections have gathered in Johannesburg, South Africa, to try to establish what is going wrong and discuss solutions.

    October 13, 2022
    General
    The Telegraph

  • Monkeypox Vaccine Appears Effective, but Studies Have Mixed Results

    The MVA-BN smallpox and monkeypox vaccine, sold as Imvanex in Europe and Jynneos in the United States, has now been widely rolled out in several countries, but questions remain about its effectiveness in real-world use. A recent US analysis suggests that men who received the vaccine were about 14 times less likely to develop monkeypox, but experts say more research is needed before relying on vaccination alone to curb the monkeypox outbreak.

    October 13, 2022
    General
    aidsmap

  • Five Takeaways from the 2022 US Conference on HIV/AIDS (USCHA)

    After scrapping the in-person USCHA conference for two years due to COVID-19, and efforts to locate the event in San Juan, Puerto Rico being threatened by two hurricanes – including Ian only weeks ago – it would seem the industrious folks at NMAC (which produces USCHA) made the conference happen this year through sheer force of will. Thank goodness. It was the right call.

    October 13, 2022
    General
    POZ Magazine

  • HIV: The Forgotten Pandemic

    From San Francisco to Asia, the number of HIV infections is rising at a speed that’s alarming US and global health officials. In 2021, 1.5 million people were infected with HIV, a million more than public health officials' target, according to a Joint United Nations Programme on HIV/AIDS estimate. Experts suspect the COVID-19 pandemic played a role. John Nkengasong, the leader of the biggest anti-AIDS program in the world — the US President’s Emergency Plan for AIDS Relief — spoke to Future Pulse about his plan to fight back.

    October 12, 2022
    General
    POLITICO

  • Seroconversion With DVR Use Did Not Negatively Impact Treatment Outcome

    Clinical progression and virologic outcomes among study participants using the dapivirine vaginal ring vs. those given a placebo ring were similar, according to a recent trial.

    October 12, 2022
    PrEP
    Healio

  • First Self-Test Swab Kits for HIV Go on Sale in the UK

    Superdrug has become the first high-street retailer in the UK to offer HIV self-tests, meaning you can test yourself for HIV at home by swabbing your gums and get results back in just 20 minutes. Previously, checking for HIV required pricking your finger and testing your blood sample, with results taking up to 72 hours to come through.

    October 12, 2022
    General
    Cosmopolitan

  • Improving the HIV Response for Transgender Populations: Evidence To Inform Action

    Our knowledge about HIV among transgender populations has substantially improved since the Journal of the International AIDS Society (JIAS) published its first special issue about HIV in transgender populations in 2016. A PubMed search indicates that more than 1000 peer-reviewed manuscripts focused on HIV among transgender people have been published in the past 5 years. While this increased volume of research is heartening, the findings indicate transgender people remain disproportionately burdened by HIV globally.

    October 12, 2022
    General
    Journal of the International AIDS Society

  • Pledge Aid or Deprive Commonwealth’s Poorest in Diseases Fight, UK Warned

    Some of the poorest countries in the Commonwealth may be left unable to deploy cutting-edge UK innovations against three of the world’s deadliest diseases if Britain fails to give generously to a key international fund, the UK government has been warned. Peter Sands, the executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, said the combined death toll from the diseases could be halved in the next four years in the countries where the fund invests.

    October 11, 2022
    General
    The Guardian

  • Are People Living With HIV More Prone to Long COVID?

    People living with HIV may be more likely to develop long-term symptoms after SARS-CoV-2 infection—commonly known as long COVID—and this might be related to differences in immune function, according to research published in the October 1 edition of AIDS. The study, conducted by Michael Peluso, MD, of the University of California San Francisco (UCSF), and a team of colleagues that includes long-time HIV cure researchers Steven Deeks, MD, and Timothy Henrich, MD, found that HIV status “strongly predicted” long COVID.

    October 11, 2022
    General
    POZ Magazine

  • Duke Receives Federal Funding for HIV Vaccine Research

    The Duke Human Vaccine Institute (DHVI) and the Department of Surgery at Duke University School of Medicine received a grant from the National Institute of Allergy and Infectious Diseases for HIV vaccine research that could total $25.9 million with full funding over five years.

    October 11, 2022
    HIV Vaccine
    News Medical

  • Is an HIV Vaccine on the Horizon?

    HIV is a virus that attacks the body’s immune system. If not treated, it can lead to AIDS and there is no effective cure at present. HIV therefore remains a key focus on many researchers in the drug discovery industry. Now, scientists from Scripps Research, the International AIDS Vaccine Initiative (IAVI), the Ragon Institute and Moderna have made critical advances in developing an effective vaccine against HIV.

    October 10, 2022
    HIV Vaccine
    Drug Target Review

  • Should Adult Men Get Circumcised?

    There are a variety of reasons why an adult male would want to get circumcised. These can be broadly split into medical and non-medical reasons. When we look at medical reasons, one common indication for a circumcision would be the treatment of recurrent infections of the foreskin and glans penis, also known as balanoposthitis, or simply, balanitis.

    October 10, 2022
    Voluntary Medical Male Circumcision
    The Star

  • Pharmacist Insights: Descovy and Truvada for HIV Pre-Exposure Prophylaxis

    Clinical studies have shown similar efficacy between 2 pre-exposure prophylaxis (PrEP) drugs for individuals at risk for HIV infection. Findings from the 96-week DISCOVER trial show that emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets, F/TAF (Descovy, Gilead) is just as effective as emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg F/TDF (Truvada).

    October 10, 2022
    PrEP
    Pharmacy Times

  • HIV PrEP Stigma Persists, Even Among Men Who Have Sex With Men

    When taken as directed, pre-exposure prophylaxis (PrEP) reduces the risk of HIV infection by 99 percent. Despite having a disproportionately high risk of contracting HIV, men who have sex with men (MSM) have insufficient PrEP uptake and adherence. Investigators from the University of Michigan School of Nursing wanted to determine whether negative stigma surrounding HIV was preventing MSM from using PrEP.

    October 10, 2022
    PrEP
    Contagion Live

  • New Efforts To Raise Uptake of PrEP in War on HIV/AIDS

    The Kenya Medical Research Institute (Kemri) has just concluded a study on how to increase the reach of HIV PrEP in Kenya using private pharmacies. The study, being the first of its kind in the country, is seeking ways to reduce and prevent the spread of HIV. The department of Center for Microbiology Research (CMR) and Research Care and Training Programme (RCTP) led the project which was conducted for one and a half years.

    October 10, 2022
    PrEP
    The Standard

  • COVID-19: Hopes for Oxford Nasal Vaccine Dealt Blow After Poor Trial Results

    Hopes of distributing the Oxford/AstraZeneca COVID-19 vaccine as a nasal spray have been dealt a blow after researchers said it performed poorly in its first clinical trial. The underwhelming results have led scientists to abandon plans to develop the spray in its current form, with hopes now resting on different formulations of the vaccine and more complex delivery devices, such as nebulisers that can deliver medicines deep into the lungs.

    October 10, 2022
    General
    The Guardian

Published Research

Announcements